Primary salivary gland lymphoma: A clinicopathologic study of 23 cases in Taiwan
Primary salivary gland lymphoma: A clinicopathologic study of 23 cases in Taiwan
复制标题
DOI：
10.1159/000081273
复制
发表时间：
2004-01-01
影响因子：
2.4
通讯作者：
Tang, CC
中科院分区：
文献类型：
--
作者：
Dunn, P;Kuo, TT;Tang, CC
1990年至2001年，23例原发性涎腺淋巴瘤被诊断。腮腺13例，颌下腺9例，小涎腺1例。淋巴瘤累及涎腺以外的部位：颈部淋巴结7例，骨髓3例，腋窝淋巴结3例，鼻咽2例，腹部淋巴结2例，腭部、结膜下和脾脏各1例。组织学检查：19例为粘膜相关淋巴组织（MALT）淋巴瘤，13例为肌上皮性涎腺炎，3例为弥漫性大细胞淋巴瘤，1例为滤泡性淋巴瘤。I期6例，II期4例，III期1例，IV期12例。23例患者中有8例（35%）在NHL诊断之前或之后患有自身免疫性疾病，并且均患有MALT淋巴瘤。4例腮腺MALT淋巴瘤患者有原发或继发性干燥综合征。甲状腺功能亢进、系统性红斑狼疮、膜增生性肾小球肾炎和冷球蛋白血症各1例。6例I期患者均在治疗后17 ~ 84个月（中位44个月）达到完全缓解（CR），无复发。除1例IV期滤泡性淋巴瘤患者在未接受治疗的情况下于3.5个月时死亡外，其余16例患者均达到CR。然而，在II-IV期患者中观察到高复发率（9/16，56%）。这些患者倾向于在原部位复发，但在化疗或放疗后再次达到CR。1例MALT淋巴瘤患者在复发期间发生组织学转化为弥漫性大淋巴瘤，死于难治性疾病。总的来说，只有2名患者死亡。5年总生存率和无复发生存率分别为94.7%和51.4%。因此，涎腺淋巴瘤被证明是一种惰性疾病。版权所有（C）2004 S. Karger AG，巴塞尔。
Twenty-three patients with primary salivary gland lymphoma were diagnosed between 1990 and 2001. The sites of involvement were the parotid gland in 13, the submandibular gland in 9 and the minor salivary gland in 1. The sites of lymphoma involvement beyond the salivary glands were the cervical lymph nodes in 7, bone marrow in 3, the axillary lymph nodes in 3, the nasopharynx in 2, the abdominal lymph nodes in 2, the palate, the subconjunctiva, and the spleen in 1 each patient. Histologically, 19 patients had lymphomas of mucosa-associated lymphoid tissue (MALT) with myoepithelial sialadenitis in 13, 3 patients had diffuse large cell lymphomas and 1 had follicular lymphoma. Six patients were in stage I, 4 in II, 1 in III and 12 in IV. Eight of 23 patients (35%) had autoimmune diseases before or after the diagnosis of NHL and all suffered from MALT lymphoma. Four patients with parotid MALT lymphoma had primary or secondary Sjogren's syndrome. One each patient suffered from hyperthyroidism, systemic lupus erythematosus, membranoproliferative glomerulonephritis and cryoglobulinemia, respectively. All the 6 stage I patients had achieved complete remission (CR) without relapses 17 - 84 months ( median 44 months) after treatment. Excluding a stage IV patient with follicular lymphoma who died at 3.5 months without treatment, CR was achieved in all of the remaining 16 patients. However, a high relapse rate (9/16, 56%) was noted in stage II-IV patients. These patients tended to relapse in the original sites, but achieved CR again after chemotherapy or radiotherapy. One patient with MALT lymphoma developed histologic transformation into diffuse large lymphoma during relapse and died of refractory disease. Overall, only 2 patients succumbed. The overall survival and relapse-free survival rates at 5 years were 94.7 and 51.4%, respectively. Thus, salivary gland lymphoma proved to be an indolent disease. Copyright (C) 2004 S. Karger AG, Basel.